Evaluation of the efficacy of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositis

Phase 2

Recruiting

• Conditions: Squamous cell carcinoma, adenosquamous carcinoma, basal cell carcinoma

• Registration Number: JPRN-jRCTs062220023
• Lead Sponsor: Takano HIdeyuki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-05-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1.Patients who are histologically diagnosed as squamous cell carcinoma, adenosquamous carcinoma, or basal cell carcinoma by endoscopic biopsy of the primary esophageal lesion
2.Patients whose treatment policy in esophageal surgery is preoperative chemotherapy with DFP and surgery
3.Patients whose Performance status (PS) is 0, 1 or 2 according to ECOG criteria
4.Patients who have written consent to participate in the study

Exclusion Criteria

1.Patients with cancer lesions in the oral cavity
2.Patients with obvious wounds in the oral cavity other than oral mucositis
3.Patients known to be allergic to the components of Epicil
4.Patients participating in other clinical trials or clinical studies
5.Female patients who are breastfeeding, pregnant, or may become pregnant
6.In addition, patients who find it difficult to carry out this study at the discretion of the researcher

Study & Design

• Study Type: Interventional
• Study Design: Not specified